Dengue Vaccine Market is estimated to increase at a growth rate of 12.9% CAGR over the forecast period from 2024 to 2030.
The global Dengue Vaccine Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Category (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines), By Product (CTD-TDV, Others), By Route of Administration (Subcutaneous, Others), By Application (Hospitals and clinic, Government Institutes, Specialty Clinics, Others), By End-User (Healthcare, Others).
An Introduction to Dengue Vaccine Market in 2024
The Dengue Vaccine Market focuses on vaccines and immunizations targeting dengue fever, a mosquito-borne viral infection caused by the dengue virus transmitted by Aedes mosquitoes. Dengue vaccines aim to prevent dengue infection, reduce disease severity, and decrease the risk of dengue hemorrhagic fever and dengue shock syndrome. Market developments include the introduction of dengue vaccines, clinical trials for vaccine efficacy and safety, and strategies for dengue prevention and public health interventions in endemic regions.
Dengue Vaccine Market Competitive Landscape
The global Dengue Vaccine Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Dengue Vaccine Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Dengue Vaccine Industry include- Biological E Ltd, GeneOne Life Science Inc, GlaxoSmithKline Plc, Medigen Vaccine Biologics Corp, Merck & Co. Inc, Panacea Biotec Ltd, Sanofi Pasteur Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd.
Dengue Vaccine Market Trend: Increasing Focus on Dengue Prevention Through Vaccination Programs
A significant trend in the dengue vaccine market is the growing emphasis on dengue prevention through vaccination programs. Dengue fever is a mosquito-borne viral infection that poses a significant public health challenge, particularly in tropical and subtropical regions where the Aedes mosquito vector thrives. With the increasing incidence of dengue outbreaks and the associated morbidity and mortality, there is a heightened awareness of the need for effective vaccination strategies to control the spread of the disease. Governments, public health agencies, and international organizations are increasingly investing in vaccination campaigns aimed at immunizing at-risk populations, including children and adults living in endemic areas. Moreover, advancements in vaccine research and development have led to the introduction of novel dengue vaccines with improved efficacy, safety, and coverage, driving the expansion of vaccination programs and adoption of routine immunization practices to mitigate the burden of dengue fever worldwide.
Dengue Vaccine Market Driver: Rising Global Burden of Dengue Fever and Dengue Hemorrhagic Fever
A key driver fueling the dengue vaccine market is the rising global burden of dengue fever and dengue hemorrhagic fever. Dengue infection represents a significant public health threat, with an estimated 390 million dengue infections occurring annually worldwide. The disease burden is particularly pronounced in tropical and subtropical regions of Asia, the Americas, and Africa, where environmental factors conducive to mosquito breeding and viral transmission contribute to the endemicity of dengue fever. Dengue outbreaks can strain healthcare systems, overwhelm healthcare facilities, and impose substantial economic costs on affected communities. The increasing incidence of severe dengue cases, including dengue hemorrhagic fever and dengue shock syndrome, underscores the urgent need for effective preventive measures, including vaccination. As the global burden of dengue fever continues to escalate, there is growing recognition of the value of vaccination as a cost-effective strategy to reduce dengue-related morbidity and mortality, alleviate healthcare burdens, and promote population health resilience against dengue outbreaks.
Dengue Vaccine Market Opportunity: Expansion of Dengue Vaccine Access and Affordability in Endemic Regions
An opportunity for the dengue vaccine market lies in the expansion of vaccine access and affordability in endemic regions. Despite the availability of dengue vaccines, access to vaccination remains limited in many high-burden countries due to various challenges, including vaccine supply constraints, logistical barriers, and socioeconomic disparities. To address these barriers and enhance vaccine uptake, there is a need for collaborative efforts among governments, international organizations, vaccine manufacturers, and healthcare stakeholders to prioritize dengue vaccination as a public health intervention. Strategies such as vaccine subsidies, tiered pricing models, and innovative financing mechanisms can help improve vaccine affordability and accessibility for vulnerable populations in endemic areas. Additionally, investments in infrastructure development, cold chain logistics, and healthcare workforce capacity building are essential to strengthen vaccination delivery systems and ensure equitable distribution of dengue vaccines. By enhancing vaccine access and affordability, stakeholders can accelerate progress towards achieving dengue control and elimination goals, ultimately reducing the global burden of dengue fever and improving public health outcomes for affected communities.
Market Share Analysis: Dengue Vaccine for Chimeric Live Attenuated Vaccines is the fastest growing segment in the Dengue Vaccine industry
Among the categories of dengue vaccines, chimeric live attenuated vaccines are experiencing the fastest growth. This surge is driven by the innovative approach of chimeric vaccines, which combine elements of different dengue virus serotypes to induce a protective immune response while minimizing the risk of adverse reactions. Chimeric live attenuated vaccines offer the advantage of enhanced safety and efficacy compared to traditional live attenuated vaccines, as they are engineered to reduce the risk of vaccine-induced dengue virus infection and disease enhancement. The leading product in this category, CTD-TDV, has shown promising results in clinical trials, demonstrating its ability to provide robust and durable immunity against dengue fever. Furthermore, the subcutaneous route of administration for chimeric live attenuated vaccines offers convenience and ease of delivery, making them suitable for mass vaccination campaigns and routine immunization programs. As governments, healthcare organizations, and public health agencies intensify efforts to combat dengue fever, particularly in regions where the disease is endemic, the demand for chimeric live attenuated vaccines is expected to continue growing rapidly. With their potential to significantly reduce the global burden of dengue fever and prevent outbreaks, chimeric live attenuated vaccines represent a crucial tool in the fight against this mosquito-borne viral infection.
Dengue Vaccine Market Segmentation
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Dengue Vaccine Companies
Biological E Ltd
GeneOne Life Science Inc
GlaxoSmithKline Plc
Medigen Vaccine Biologics Corp
Merck & Co. Inc
Panacea Biotec Ltd
Sanofi Pasteur Ltd
Serum Institute of India Pvt. Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
* List not Exhaustive
Reasons to Buy the Dengue Vaccine Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Dengue Vaccine Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Dengue Vaccine Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Dengue Vaccine Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Dengue Vaccine Market Size Outlook, $ Million, 2021 to 2030
3.2 Dengue Vaccine Market Outlook by Type, $ Million, 2021 to 2030
3.3 Dengue Vaccine Market Outlook by Product, $ Million, 2021 to 2030
3.4 Dengue Vaccine Market Outlook by Application, $ Million, 2021 to 2030
3.5 Dengue Vaccine Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Dengue Vaccine Industry
4.2 Key Market Trends in Dengue Vaccine Industry
4.3 Potential Opportunities in Dengue Vaccine Industry
4.4 Key Challenges in Dengue Vaccine Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Dengue Vaccine Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Dengue Vaccine Market Outlook by Segments
7.1 Dengue Vaccine Market Outlook by Segments, $ Million, 2021- 2030
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
8 North America Dengue Vaccine Market Analysis and Outlook To 2030
8.1 Introduction to North America Dengue Vaccine Markets in 2024
8.2 North America Dengue Vaccine Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Dengue Vaccine Market size Outlook by Segments, 2021-2030
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
9 Europe Dengue Vaccine Market Analysis and Outlook To 2030
9.1 Introduction to Europe Dengue Vaccine Markets in 2024
9.2 Europe Dengue Vaccine Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Dengue Vaccine Market Size Outlook by Segments, 2021-2030
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
10 Asia Pacific Dengue Vaccine Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Dengue Vaccine Markets in 2024
10.2 Asia Pacific Dengue Vaccine Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Dengue Vaccine Market size Outlook by Segments, 2021-2030
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
11 South America Dengue Vaccine Market Analysis and Outlook To 2030
11.1 Introduction to South America Dengue Vaccine Markets in 2024
11.2 South America Dengue Vaccine Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Dengue Vaccine Market size Outlook by Segments, 2021-2030
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
12 Middle East and Africa Dengue Vaccine Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Dengue Vaccine Markets in 2024
12.2 Middle East and Africa Dengue Vaccine Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Dengue Vaccine Market size Outlook by Segments, 2021-2030
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Biological E Ltd
GeneOne Life Science Inc
GlaxoSmithKline Plc
Medigen Vaccine Biologics Corp
Merck & Co. Inc
Panacea Biotec Ltd
Sanofi Pasteur Ltd
Serum Institute of India Pvt. Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
